Ticker

Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 19,055 shares, a growth of 69.4% from the February 12th total of 11,249 shares. Currently, 0.4% of the company's stock are short sold.

MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced  that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place…

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies –

Athira Pharma (NASDAQ: ATHA - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Risk and Volatility Athira Pharma has a

− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter. Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.